RemeGen荣昌生物

What RemeGen荣昌生物 does

RemeGen Co., Ltd. (荣昌生物制药（烟台）股份有限公司, 688331.SH / 09995.HK) is a China-headquartered biopharmaceutical company founded in 2008 by Wang Weidong and Dr. Fang Jianmin, developing, manufacturing, and commercializing innovative biologic drugs for autoimmune diseases, oncology, and ophthalmology. Its commercial portfolio comprises two core products: Telitacicept (RC18, brand 泰爱®), the world's first BLyS/APRIL dual-target fusion protein biologic with five NMPA-approved indications (SLE, RA, gMG, Sjogren's syndrome, and IgA nephropathy), and Disitamab Vedotin (RC48, brand 爱地希®), China's first domestically developed HER2-targeting antibody-drug conjugate (ADC) approved for gastric cancer, urothelial carcinoma, and HER2-expressing breast cancer. The underlying platform technology spans proprietary antibody fusion protein engineering, ADC technology with novel toxins and linkers, bispecific antibodies (including PD-1/VEGF), and a next-generation Payload Recovery ADC (PR-ADC) platform — backed by 600+ patent applications and 40+ active clinical trials across eight clinical-stage pipeline programs.

Name

RemeGen荣昌生物

Legal name

荣昌生物制药（烟台）股份有限公司

Website

https://remegen.cn

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

RemeGen (荣昌生物) is a China-based A+H-listed biopharmaceutical company that develops, manufactures, and commercializes first-in-class biologics including Telitacicept (BLyS/APRIL dual-target fusion protein for autoimmune diseases) and Disitamab Vedotin (HER2 ADC for oncology), serving Chinese hospitals across autoimmune, oncology, and ophthalmology therapeutic areas.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Biologic drug development
• Antibody drug conjugates
• Autoimmune disease therapeutics
• Oncology biologics
• Fusion protein drugs

Headquarters

HQ city

Yantai

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Domestic Product Sales: Domestic commercial sales of approved products including Telitacicept (RC18) and Disitamab Vedotin (RC48). 2025 domestic sales reached 22.71 billion RMB, growing 34% YoY. Continuous growth driven by hospital access expansion and new indication approvals.
2. BD Licensing/Out-licensing: Upfront payments, milestone payments, and royalties from out-licensing agreements with global pharmaceutical partners. RC48 licensed to Seagen (2021) for $2.6B; RC18 licensed to Vor Bio for $4.23B; RC28 licensed to Santen for ~RMB 1.275B; RC148 licensed to AbbVie for $5.6B including $650M upfront.
3. Milestone Payments: Development, regulatory, and commercial milestone payments from partnership agreements, contributing significant non-recurring revenue.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

RemeGen discovers, develops, manufactures, and commercializes innovative biologic drugs targeting autoimmune diseases, oncology, and ophthalmology. Its commercial portfolio includes Telitacicept (RC18), the world's first BLyS/APRIL dual-target fusion protein biologic, and Disitamab Vedotin (RC48), China's first domestically developed HER2-targeting antibody-drug conjugate (ADC). The company also licenses its pipeline assets to global pharmaceutical partners for international markets.

Product overview

RemeGen荣昌生物 is a biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative biologic drugs. The company's portfolio includes two marketed products: 泰它西普 (Telitacicept/RC18), a BLyS/APRIL dual-target fusion protein for autoimmune diseases, and 维迪西妥单抗 (Disitamab vedotin/RC48), China's first self-developed HER2-targeting ADC for oncology. The pipeline includes multiple bispecific antibodies and ADCs such as RC148 (PD-1/VEGF bispecific), RC28 (ophthalmology), RC88, RC278, and RC288 (PSMA/B7H3 bispecific ADC), covering autoimmune diseases, oncology, and ophthalmology therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

• 泰爱®: 泰它西普（RC18）的商品名，BLyS/APRIL双靶点融合蛋白创新药，用于治疗系统性红斑狼疮、类风湿关节炎、全身型重症肌无力、干燥综合征、IgA肾病等自身免疫疾病。
• 爱地希®

Products and services

• Telitacicept (RC18) / 泰它西普 (Brand: 泰爱®) World's first BLyS/APRIL dual-target fusion protein innovative biologic drug for autoimmune diseases. Indicated for SLE, RA, gMG, Sjogren's syndrome, and IgA nephropathy. Targets B-cell activating factor and a proliferation-inducing ligand pathways.
• Disitamab Vedotin (RC48) / 维迪西妥单抗 (Brand: 爱地希®)

Quantifiable outcome

• Telitacicept achieved 55% UPCR reduction vs placebo (p<0.0001) in IgA nephropathy Phase III
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• AbbVie (艾伯维)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2026Licensing agreement for RC148 (PD-1/VEGF bispecific antibody). AbbVie获得RC148在大中华区以外地区的独家开发、生产和商业化权利。荣昌生物获得6.5亿美元首付款，并有资格获得最高达49.5亿美元的开发、监管和商业化里程碑付款，以及两位数分级特许权使用费。总交易额56亿美元。
• Vor BiocoreOEM/ Whitelabel/ Licensing Partner · 1 June 2025Licensing agreement for RC18 (Telitacicept) covering global markets outside Greater China. Vor Bio received rights for global development of autoimmune indications including myasthenia gravis and Sjogren's syndrome. Deal includes $45M upfront, $80M warrant, up to $4.105B milestones, and high single-digit to double-digit royalties. Total deal value $4.23B.
• Santen China (参天中国)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2025Licensing agreement for RC28 (VEGF/FGF dual-target fusion protein) for ophthalmology. Covers Greater China and multiple Asian markets. Deal includes 250M RMB upfront, up to 520M RMB development milestones, up to 525M RMB sales milestones, and tiered royalties.
• SeagencoreOEM/ Whitelabel/ Licensing Partner · 1 August 2021Licensing agreement for RC48 (Disitamab Vedotin). Original deal valued at $2.6 billion. Seagen获得RC48在大中华区以外的全球独家开发、生产和商业化权利。

Scale indicators13 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Daiichi Sankyo: Daiichi Sankyo is the global ADC platform leader (Enhertu/Datroway) with HER2 and Trop-2 franchises that directly compete with RemeGen's Disitamab Vedotin. As a larger established Japanese pharma with deep ADC technology, it represents the dominant incumbent whose commercial success benchmarks the upside ceiling for HER2 ADC class.
• Pfizer: Pfizer acquired Seagen in 2023 and thereby inherited the global development and commercialization rights to RC48 (Disitamab Vedotin) under the original 2021 USD 2.6B licensing deal. Pfizer's strategic priorities for the Seagen ADC pipeline directly shape the international commercialization trajectory of RemeGen's flagship oncology asset.
• AstraZeneca: AstraZeneca is a global oncology and immunology leader with HER2 ADC (in collaboration with Daiichi Sankyo) and autoimmune biologics (Saphnelo for SLE) that compete with RemeGen's portfolio in both therapeutic areas. Its breadth of operations and global commercial reach establish the scale benchmark for out-licensed RemeGen assets.
• Hansoh Pharmaceutical (翰森制药): Hansoh is one of China's leading innovative pharma companies with a deep oncology pipeline and biologic assets competing in similar indications to RemeGen. Comparable as a domestically focused, NRDL-driven commercial player with growing biologic portfolio exposure.
• Hengrui Pharma (恒瑞医药): Hengrui is China's largest domestic pharmaceutical company with a broad oncology, autoimmune, and biologic pipeline competing directly with RemeGen in Chinese hospital channels. As the largest incumbent, it anchors the competitive dynamics of NRDL negotiations and hospital tender processes that govern RemeGen's domestic commercial trajectory.

Direct peers

• BeiGene: BeiGene is a globally commercialized Chinese biotech with BRUKINSA (zanubrutinib) as a flagship hematology asset. It offers a comparable profile of China-origin biologics, A+H/US listings, deep commercial infrastructure in China, and global out-licensing/partnership strategy similar to RemeGen's AbbVie and Vor Bio deals.
• Akeso (康方生物): Akeso is a Chinese biotech with the PD-1/VEGF bispecific ivonescimab that directly competes with RemeGen's RC148 in non-small cell lung cancer and other oncology indications. Both companies are China-based, platform-driven biologic innovators pursuing global out-licensing deals with similar therapeutic focus areas (oncology/immunology).
• Innovent Biologics (信达生物): Innovent is a leading Chinese biologics innovator with multiple approved products and PD-1 leadership (sintilimab), pursuing both domestic commercial sales and global BD partnerships. Comparable to RemeGen in therapeutic focus (oncology, autoimmune), biologics platform depth, and commercial model (NRDL-driven hospital sales).
• Junshi Biosciences (君实生物): Junshi is a Chinese biotech that pioneered PD-1 (toripalimab) and has pursued combination therapies with partners including Coherus. RemeGen's RC48 + toripalimab combination in urothelial carcinoma creates direct clinical collaboration overlap, and Junshi shares RemeGen's A+H dual-listing, biologics platform, and indication-expansion strategy.

Emerging players

• Cstone Pharmaceuticals (基石药业): Cstone is a smaller Chinese biotech with biologic and bispecific antibody assets pursuing similar out-licensing and indication-expansion strategies. While smaller in scale, it represents a comparable emerging Chinese biologic innovator that competes for global partner interest and KOL mindshare in similar indications.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RemeGen荣昌生物